Dr. Petros Grivas is board-certified medical oncologist with vast experience and high expertise in genitourinary (GU) cancers. He has had a main role in several clinical trials leading to FDA approval of new drugs for urothelial cancer, including avelumab and Trodelvy®. Dr. Grivas is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists and other healthcare providers, mentoring numerous trainees, leading large innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to personalized and outstanding patient care, efficient clinical operations, and believes in optimal patient-physician relationship as well as community outreach. Dr. Grivas is the Clinical Director of the GU Cancers Program and Professor at the Dept. of Medicine, Division of Hematology Oncology, University of Washington and at the Clinical Research Division at Fred Hutchinson Cancer Center. He received his MD and PhD in Greece in 2005 and 2009, respectively. He completed his Internal Medicine Residency at the Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia) in 2010, and a Hematology/Oncology Fellowship at the University of Michigan (Ann Arbor) in 2013. Dr. Grivas was Clinical Lecturer before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland)